Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I, open-label, fixed-sequence, crossover study to investigate the effect of itraconazole (CYP3A inhibitor) and phenytoin (CYP3A inducer) on BIIB113 and the effect of BIIB113 on midazolam (CYP3A substrate) in healthy participants

Next Previous
Search
Trial Profile

A Phase I, open-label, fixed-sequence, crossover study to investigate the effect of itraconazole (CYP3A inhibitor) and phenytoin (CYP3A inducer) on BIIB113 and the effect of BIIB113 on midazolam (CYP3A substrate) in healthy participants

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 31 Dec 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs BIIB 113 (Primary) ; Itraconazole (Primary) ; Midazolam (Primary) ; Phenytoin (Primary)
  • Indications Alzheimer's disease
  • Focus Pharmacokinetics
  • Sponsors Biogen

    • Most Recent Events

    • 29 Dec 2023 Status changed from recruiting to completed.
    • 17 Nov 2023 Recruitment completion is expected on 4 Dec 2023, according to ISRCTN Clinical Trials Registry record.
    • 17 Nov 2023 Planned End Date changed from 15 Jan 2024 to 27 Dec 2023.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top